Trial Profile
The safety and efficacy of tocilizumab in patients with neuromyelitis optica
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2015
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Neuromyelitis optica
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2015 New trial record